MP39-17 MITOCHONDRIAL DNA COPY NUMBER VARIATION AS A POTENTIAL PREDICTOR OF RENAL CELL CARCINOMA.

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Eman Elsayed ◽  
Mohamed Mohieeldin Hashad ◽  
Eman Elgohary
Keyword(s):  
Renal Cell Carcinoma ◽  
Mitochondrial Dna ◽  
Copy Number Variation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Copy Number ◽  
Potential Predictor ◽  
Dna Copy Number Variation ◽  
Mitochondrial Dna Copy Number ◽  
Number Variation

scholarly journals Cell-free mitochondrial DNA copy number variation in head and neck squamous cell carcinoma: A study of non-invasive biomarker from Northeast India

Tumor Biology ◽  
2017 ◽  
Vol 39 (10) ◽  
pp. 101042831773664 ◽  
Author(s):  
Manish Kumar ◽  
Shilpee Srivastava ◽  
Seram Anil Singh ◽  
Anup Kumar Das ◽  
Ganesh Chandra Das ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Mitochondrial Dna ◽  
Copy Number Variation ◽  
Cell Carcinoma ◽  
Copy Number ◽  
Northeast India ◽  
Dna Copy Number Variation ◽  
Non Invasive ◽  
Mitochondrial Dna Copy Number ◽  
Number Variation

scholarly journals A Case-Control Study of Peripheral Blood Mitochondrial DNA Copy Number and Risk of Renal Cell Carcinoma

PLoS ONE ◽  
2012 ◽  
Vol 7 (8) ◽  
pp. e43149 ◽  
Author(s):  
Mark P. Purdue ◽  
Jonathan N. Hofmann ◽  
Joanne S. Colt ◽  
Mirjam Hoxha ◽  
Julie J. Ruterbusch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Mitochondrial Dna ◽  
Cell Carcinoma ◽  
Peripheral Blood ◽  
Renal Cell ◽  
Copy Number ◽  
Case Control Study ◽  
Case Control ◽  
Mitochondrial Dna Copy Number ◽  
Control Study

scholarly journals Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma

2016 ◽  
Vol 17 (6) ◽  
pp. 814 ◽  
Author(s):  
Chen-Sung Lin ◽  
Hui-Ting Lee ◽  
Ming-Huei Lee ◽  
Siao-Cian Pan ◽  
Chen-Yeh Ke ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Mitochondrial Dna ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Copy Number ◽  
Copy Number Alteration ◽  
Dna Copy Number ◽  
Human Renal Cell Carcinoma ◽  
Mitochondrial Dna Copy Number

Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 393-393
Author(s):  
Eric Jonasch ◽  
Suresh Thakur ◽  
Kanishka Sircar ◽  
Pheroze Tamboli ◽  
Nizar M. Tannir ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Copy Number Variation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Copy Number ◽  
Clear Cell ◽  
Response To Therapy ◽  
Antiangiogenic Agents ◽  
Cell Renal Cell Carcinoma ◽  
Number Variation

393 Background: Antiangiogenic agents (AA) are used to treat metastatic clear cell renal cell carcinoma (ccRCC). Currently there are no biomarkers of therapeutic efficacy with these agents. We have previously shown that chromosome copy number variation (CNV) is associated with poor (14q loss) or more favorable outcomes (5q31-ter gain) in nonmetastatic patients. The purpose of the current study was the impact of CNV on response, progression free survival (PFS) and on overall survival (OS) after AA in patients with metastatic ccRCC. Methods: We obtained archival FFPE or frozen tumor specimens from patients with mRCC treated with sorafenib (after tumor removal), bevacizumab or sunitinib (neoadjuvant treatment). DNA was analyzed with Affymetrix 250K Nsp SNP microarrays. We identified the presence of genomic imbalances and loss of heterozygosity (LOH) to obtain “virtual karyotypes”. We then compared CNV to outcome using Wilcoxon-Gehan statistical analysis. Results: A total of 83 patients were used to analyze CNV after treatment with AA: 22 sorafenib, 29 sunitinib, 31 bevacizumab. Gain of 8q (p = 0.036) and loss of 16q (p = 0.0031), 20p (p = 0.038) or 20q (p = 0.022) were associated with a shorter OS, whereas gain of 1q (p = 0.037) and 5q (p = 0.019) were associated with longer OS in this patient cohort. When 14q loss was combined with 8q gain, median OS was further decreased (p 0.01). Surprisingly, when assessed as a group, no specific CNV was associated with PFS. However, when compared separately, 5q gain was predictive for better PFS in sorafenib or bevacizumab treated patients (p = 0.006), but no such effect was seen in the sunitinib treated cohort. Conclusions: Our results show that chromosomal imbalances are associated with divergent clinical outcome in metastatic ccRCC patients treated with AA, and are predominantly prognostic. Dissecting out driver tumor suppressor or tumor activating genes within these chromosomal regions will guide our understanding of what defines a particularly lethal phenotype. The possibility exists that specific CNV profiles predict for response to therapy, but a larger sample size is required to validate this possibility.

scholarly journals Mitochondrial DNA Copy-Number Variation and Pancreatic Cancer Risk in the Prospective EPIC Cohort

2020 ◽  
Vol 29 (3) ◽  
pp. 681-686 ◽  
Author(s):  
Manuel Gentiluomo ◽  
Verena A. Katzke ◽  
Rudolf Kaaks ◽  
Anne Tjønneland ◽  
Gianluca Severi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mitochondrial Dna ◽  
Cancer Risk ◽  
Copy Number Variation ◽  
Copy Number ◽  
Dna Copy Number ◽  
Pancreatic Cancer Risk ◽  
Dna Copy Number Variation ◽  
Mitochondrial Dna Copy Number ◽  
Number Variation
Sign in / Sign up

Export Citation Format

Share Document